The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $5.67

Today's change+0.07 +1.25%
Updated February 10 4:00 PM EST. Delayed by at least 15 minutes.
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $5.67

Today's change+0.07 +1.25%
Updated February 10 4:00 PM EST. Delayed by at least 15 minutes.

Infinity Pharmaceuticals Inc up (U.S.)$0.07

Infinity Pharmaceuticals Inc closed up Wednesday by (U.S.)$0.07 or 1.25% to (U.S.)$5.67. Over the last five days, shares have lost 3.41% and are down 27.77% for the last year to date. This security has underperformed the S&P 500 by 50.37% during the last year.

Key company metrics

  • Open(U.S.) $5.67
  • Previous close(U.S.) $5.60
  • High(U.S.) $6.07
  • Low(U.S.) $5.51
  • Bid / Ask-- / --
  • YTD % change-27.77%
  • Volume387,243
  • Average volume (10-day)606,506
  • Average volume (1-month)828,985
  • Average volume (3-month)943,203
  • 52-week range(U.S.) $5.24 to (U.S.) $16.98
  • Beta1.60
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.64
Updated February 10 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-124.14%

Although this company's net profit margin is negative, it is above the industry average and implies that Infinity Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.79%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue91544
Total other revenue--------
Total revenue91544
Gross profit--------
Total cost of revenue--------
Total operating expense47439743
Selling / general / administrative10997
Research & development38348836
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income43-39-93-39
Interest income (expense), net non-operating00-1-1
Gain (loss) on sale of assets--------
Other--------
Income before tax43-38-93-40
Income after tax43-38-93-40
Income tax, total0----0
Net income43-38-93-40
Total adjustments to net income-1------
Net income before extra. items43-38-93-40
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items42-38-93-40
Inc. avail. to common incl. extra. items42-38-93-40
Diluted net income42-38-93-40
Dilution adjustment0------
Diluted weighted average shares50494949
Diluted EPS excluding extraordinary itemsvalue per share0.84-0.78-1.91-0.83
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.84-0.78-1.91-0.83